Nanxi Liu - Aug 27, 2021 Form 4 Insider Report for Kindred Biosciences, Inc. (KIN)

Role
Director
Signature
/s/ Nanxi Liu
Stock symbol
KIN
Transactions as of
Aug 27, 2021
Transactions value $
-$200,160
Form type
4
Date filed
8/30/2021, 02:35 PM
Previous filing
May 20, 2021
Next filing
May 27, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KIN Stock Option (right to buy) Disposed to Issuer -$200K -48K -100% $4.17 0 Aug 27, 2021 Common Stock 48K $5.08 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Nanxi Liu is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This option provided for vesting in four equal quarterly installments from the option grant date. Pursuant to the agreement and plan of merger, dated as of June 15, 2021, by and among the Elanco Animal Health Incorporated, Knight Merger Sub, Inc., and Kindred Biosciences, Inc. (the "Merger Agreement"), the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $200,160.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.